Oncology
VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven
Published in Cancer Weekly, April 8th, 2008
for presentation at the April meeting of the American Academy of Cancer
Research. -- Following the completion of enrollment in the Phase 1/2a trial of its
lead clinical candidate RAV12 in mid-February, Raven announced on March
11th that the study results had been accepted for presentation at the
American Society of Clinical Oncology in May. -- On March 13th, Raven announced that it had initiated a Phase 2 study of
RAV12 for the treatment of patients with metastatic pancreatic cancer. These and other...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-04-08)
More Articles from Cancer Weekly
- Bioengineering
New bioengineering study findings have been reported by researchers at Children's Hospital - Biopharmaceuticals
Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, into Phase 1 Clinical Trial - Breast Cancer
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports - Cancer
Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists and Collaborators in Nature Biotechnology - Cancer
Haymarket Adds Two Cancer Journals to Its Family of Clinical Publications - Cancer
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
